This level of coordinated buying by a sophisticated biotech investor like ARCH Venture Partners is highly unusual and suggests strong conviction ahead of potential clinical or strategic developments. Traders should watch for upcoming catalysts such as trial readouts, partnerships, or funding news.
Price Chart
Executive Summary
Two funds affiliated with ARCH Venture Partners collectively purchased nearly $25 million worth of Lyell Immunopharma shares in open-market transactions at $25.61 per share. This represents a significant, coordinated investment by a major biotech venture firm, signaling strong confidence in the company's future prospects.
Key Financial Metrics
Key Facts
- ARCH Venture Partners IX, LLC purchased 488,090 shares at $25.61 for $12,500,000
- ARCH Venture Fund XIII, L.P. purchased 488,090 shares at $25.61 for $12,500,000
- Total open-market purchases: $25.0M across two affiliated funds
- Transactions occurred on 2026-03-06 in a single day
- Combined purchase represents approximately 5.2% of Lyell's $477M market cap
Financial Impact
$25.0 million in insider buying, equivalent to 5.2% of market capitalization
Risk Factors
- The purchases were made by affiliated funds, not company insiders (executives or directors), so this reflects investor confidence rather than direct management sentiment
- Biotech stocks are inherently volatile and sensitive to clinical trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (2 trades, 7d window) | cluster-LYEL-1773088624224 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | Insider Cluster | $15.49 $10.53 | ▼ −32.02% | ▼ −33.00% | $9.33 (−39.77%) |
Jul 22, 2026 10w ago | EFFECT | $12.84 $15.76 | ▲ +22.74% | ▲ +19.84% | $9.33 (−27.34%) |
Jun 15, 2026 15w ago | Insider Cluster | $12.44 $13.40 | ▲ +7.72% | ▲ +7.52% | $9.33 (−25.00%) |
Jun 12, 2026 16w ago | Press Release | $13.50 $15.01 | ▲ +11.19% | ▲ +9.41% | $9.33 (−30.89%) |
Jun 8, 2026 16w ago | Press Release | $12.31 $14.04 | ▲ +14.05% | ▲ +12.42% | $9.33 (−24.21%) |
Jun 4, 2026 17w ago | Press Release | $11.97 $14.04 | ▲ +17.29% | ▲ +15.43% | $9.33 (−22.06%) |
Apr 24, 2026 22w ago | DEFA14A | $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $9.33 (−58.75%) |
Apr 15, 2026 24w ago | EFFECT | $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $9.33 (−60.86%) |
Apr 3, 2026 25w ago | S-3 | $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $9.33 (−56.98%) |
Mar 12, 2026 29w ago | Press Release | $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $9.33 (−56.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access